top of page

Restricting Patent Challenges Will Harm Small Businesses

After building momentum for weeks, congressional action on patent reform legislation is beginning to slow. The Senate Judiciary Committee has twice postponed markup of the bi-partisan PATENT Act in recent weeks. Reportedly, one reason behind the pause is a push by the pharmaceutical industry to include amendments that would limit the Patent and Trademark Office’s (PTO) authority to reevaluate the validity of issued patents at the request of third-parties that haven’t themselves been accused of infringement.


Recent Posts

See All

UFPR Statement on Introduction of the PREVAIL Act

United for Patent Reform (UFPR) today issued the following statement in opposition of the recently introduced PREVAIL Act, a bill that would essentially repeal a fundamental pillar of the America Inve

bottom of page